10-K: Keros Therapeutics Reports 2025 Profit, Advances Pipeline

Keros Therapeutics achieved net income in 2025 driven by a Takeda licensing deal, while progressing lead candidates rinvatercept and elritercept, and executing a significant capital return program.

Summary

• Reported a net income of $87.0 million for the year ended December 31, 2025, a significant improvement from a net loss of $187.4 million in 2024.
• Total revenue increased to $244.1 million in 2025 from $3.6 million in 2024, primarily due to a $200.0 million upfront payment and a $10.0 million milestone from the Takeda license agreement.
• Research and development expenses decreased by $44.0 million to $129.6 million in 2025, mainly due to the deprioritization of cibotercept and KER-047, and the transition of elritercept clinical activities to Takeda.
• General and administrative expenses increased to $46.8 million in 2025 from $40.8 million in 2024, primarily due to higher professional fees.
• Cash and cash equivalents stood at $287.4 million as of December 31, 2025, down from $559.9 million at the end of 2024, following a $375.0 million capital return program.
• The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the first half of 2028.
• Rinvatercept (KER-065) is advancing, with a Phase 2 clinical trial in Duchenne muscular dystrophy (DMD) expected to commence in Q2 2026 and engagement with regulators for a Phase 2 trial in amyotrophic lateral sclerosis (ALS) planned for H2 2026.
• Elritercept (KER-050) is in a Phase 3 RENEW clinical trial for lower-risk myelodysplastic syndromes (MDS), with the first patient dosed in July 2025, triggering a $10.0 million milestone payment from Takeda.
• Cibotercept was deprioritized in January 2025 due to pericardial effusion adverse events in its Phase 2 trial for pulmonary arterial hypertension (PAH).
• KER-047 was deprioritized in November 2023.
• The company completed a $375.0 million capital return program in October and November 2025, including repurchases from ADAR1 Capital Management and Pontifax Venture Capital, and an issuer tender offer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to the significant Takeda licensing deal and the advancement of lead product candidates, despite the deprioritization of other assets and the substantial capital return which reduced cash reserves. The shift to net income and extended cash runway are favorable, but future profitability remains dependent on successful clinical development and commercialization.

Positives

• Achieved net income of $87.0 million in 2025, a significant turnaround from a net loss of $187.4 million in 2024, primarily due to the Takeda licensing deal.
• Secured a substantial $200.0 million upfront payment and a $10.0 million development milestone from Takeda for elritercept, validating the asset's value.
• Rinvatercept showed positive initial topline results in its Phase 1 clinical trial in healthy adult volunteers, demonstrating increases in lean muscle mass, thigh muscle volume, bone mineral density, and favorable changes in fat biomarkers.
• Rinvatercept received Orphan Drug Designation for the treatment of Duchenne muscular dystrophy (DMD) in August 2025, potentially offering market exclusivity benefits.
• Elritercept received Fast Track Designation for the treatment of anemia in adults with lower-risk MDS, which may expedite its development and regulatory review.
• Preclinical data for rinvatercept demonstrated increased utrophin expression and muscle strength in a mouse model of DMD, and reduced muscle wasting in an ALS mouse model.
• Preclinical data for elritercept showed sustained and rapid effects on multiple hematopoietic cell lineages, suggesting broad therapeutic potential for cytopenias.
• The company's cash and cash equivalents of $287.4 million are projected to fund operations into the first half of 2028, providing a reasonable runway.

Negatives

• The net income in 2025 was largely driven by a one-time upfront payment from the Takeda agreement, and the company expects to continue incurring significant operating losses in the future.
• Deprioritization of cibotercept in January 2025 due to unanticipated pericardial effusion adverse events in its Phase 2 trial, leading to a pause in all material internal development activities for this asset.
• Deprioritization of the small molecule product candidate KER-047 in November 2023, pausing all development activities.
• Significant reduction in cash and cash equivalents from $559.9 million in 2024 to $287.4 million in 2025, primarily due to the $375.0 million capital return program.
• The company is no longer eligible to use its New Shelf Registration Statement as an automatic shelf registration statement and cannot offer and sell shares under the ATM Program as of December 31, 2025, limiting a previous funding source.
• The capital return program, while intended to enhance stockholder value, reduced cash reserves and may impact the ability to advance clinical development of product candidates.
• The company has a limited operating history and no products approved for commercial sale, making future success and profitability highly speculative.

Risks

• Limited operating history and anticipated continued net losses, requiring substantial additional funding.
• Heavy dependence on the success of product candidates (rinvatercept, elritercept) which are in clinical development, with potential for delays, failures, or inability to obtain marketing approval.
• Clinical trials are lengthy, expensive, and have uncertain outcomes, with potential for unforeseen events, safety issues, or failure to meet endpoints.
• Product candidates may be associated with serious adverse side effects, which could delay or halt clinical development or limit marketing approval (e.g., cibotercept's pericardial effusion).
• Difficulty in enrolling sufficient patients in clinical trials, especially for rare or orphan diseases, leading to delays or termination.
• Interim, topline, and preliminary clinical data may change as more data become available and are subject to audit and verification, potentially differing materially from final results.
• Reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) for supply and conduct of studies, posing risks of delays, quality issues, or non-compliance.
• Significant competition from other biotechnology and pharmaceutical companies with greater resources and expertise.
• Challenges in protecting intellectual property, including obtaining and maintaining patents, defending against infringement claims, and potential for trade secret misappropriation.
• Exposure to costly and damaging product liability claims during clinical testing or commercialization.
• Unfavorable third-party coverage and reimbursement practices, as well as pricing regulations, could limit market acceptance and profitability.
• Public health crises, geopolitical tensions (e.g., Russia-Ukraine, Middle East wars), and economic instability could adversely impact business operations, supply chains, and clinical trials.
• Cybersecurity threats and security incidents could lead to regulatory investigations, litigation, business disruptions, and reputational harm.
• Changes in tax laws or regulations, and limitations on net operating loss (NOL) carryforwards due to ownership changes (e.g., Section 382 limitations), could adversely affect financial results.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances rinvatercept into Phase 2 clinical trials for DMD (Q2 2026) and ALS (H2 2026 regulator engagement), and continues research and development of other product candidates. It anticipates needing substantial additional funding beyond its current cash runway into the first half of 2028, which it plans to secure through equity offerings, debt financings, or new collaborations. The company also plans to distribute 25% of net cash proceeds from the Takeda Agreement to stockholders on or before December 31, 2028.

Management Comments

• We are a leader in understanding the role of the TGF-beta family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues.
• Rinvatercept has the potential to increase skeletal muscle regeneration, increase muscle size and strength, reduce body fat, reduce fibrosis of the skeletal muscle and increase bone strength.
• Elritercept has the potential to provide benefit to patients suffering from red blood cell and platelet differentiation and maturation defects occurring across the spectrum from early through terminal stages of hematopoiesis.
• Our strategy focuses on the role of members of the TGF-beta family of proteins in the development of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood.
• We believe that rinvatercept has the potential to treat multiple pathophysiologies of DMD by improving muscle and bone strength and reducing fat mass and cardiac fibrosis.
• We believe that rinvatercept has the potential to maximize the functional strength of healthy, connected muscle fibers, allowing them to compensate for atrophied fibers and motor units in ALS.
• We believe elritercept has the potential to overcome limitations of current treatment options for MDSand myelofibrosis-associated cytopenias.
• We believe, based on our previous experience with ActRII ligand traps using endogenous and wild-type sequences, that observations in preclinical rodent models have the potential to translate to humans in the clinic.
• We are committed to fostering a culture of integrity and ensuring each of our employees is equipped with resources to help them do the right thing.

Industry Context

StockSavvy.ai notes that Keros Therapeutics operates in highly competitive biopharmaceutical sectors, particularly in rare diseases like DMD, ALS, MDS, and myelofibrosis. The deprioritization of cibotercept highlights the inherent risks and high failure rates in drug development, even for promising candidates. The strategic licensing deals with Takeda and Hansoh for elritercept are crucial for validating its pipeline and securing non-dilutive funding, a common strategy for smaller biotechs to de-risk and advance programs. The capital return program, while reducing cash, could be seen as a move to enhance shareholder value and optimize capital structure following significant licensing revenue, but also signals a more focused pipeline. The competitive landscape includes major pharmaceutical companies with greater resources, and the ongoing evolution of regulatory frameworks (e.g., EU HTA Regulation, US drug pricing reforms) adds complexity and potential pressure on future commercialization and profitability.

Comparison to Industry Standards

• For Duchenne Muscular Dystrophy (DMD), current FDA-approved therapies include corticosteroids (EMFLAZA, Agamree) and exon-skipping drugs (EXONDYS 51, VYONDYS 53, AMONDYS 45, VILTEPSO) from companies like Sarepta and Nippon Shinyaku. ELEVIDYS, a gene therapy from Sarepta, received accelerated approval but faced a temporary pause due to fatal liver injury reports, highlighting the safety challenges in gene therapy. Duvyzat (givinostat) from Italfarmaco S.p.A. was also approved but carries risks of myelosuppression. Keros's rinvatercept aims to treat multiple pathophysiologies, potentially offering a broader benefit compared to mutation-specific or symptom-managing therapies.
• In Amyotrophic Lateral Sclerosis (ALS), approved therapies like riluzole, edaravone, and tofersen offer limited benefits, primarily symptom relief. Sodium phenylbutyrate and taurursodiol was withdrawn after negative Phase 3 results. Keros's rinvatercept, targeting skeletal muscle, aims to preserve muscle function, a differentiated approach compared to existing treatments that do not address underlying disease progression for the majority of patients.
• For Myelodysplastic Syndromes (MDS) and myelofibrosis-associated cytopenias, current treatments include red blood cell and platelet transfusions, erythropoiesis-stimulating agents (ESAs), and Reblozyl (Merck/Bristol-Myers Squibb) for specific MDS patient subsets (RS positive). Imetelstat (RYTELO) from Geron Corporation was recently approved for transfusion-dependent anemia in lower-risk MDS. JAK inhibitors (Jakafi, Inrebic, Vonjo) for myelofibrosis often exacerbate cytopenias. Keros's elritercept, designed to affect multiple stages of hematopoietic differentiation, aims to provide broader benefit across MDS patient populations (including non-RS) and address multiple cytopenias simultaneously, potentially offering an advantage over therapies with more limited mechanisms or patient populations.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material arbitration or legal proceedings. Litigation can be costly and divert management resources, regardless of outcome.

Related Party Transactions

• Repurchased 10,176,595 shares of common stock from entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital for $180.6 million on October 15, 2025. Tomer Kariv and Ran Nussbaum, representatives of Pontifax, resigned from the board in connection with these agreements.

Stakeholder Impact

• Shareholders: Benefited from a $375.0 million capital return program, but also experienced a reduction in cash reserves and potential future dilution from capital raises. The Stockholder Rights Plan aims to protect against hostile takeovers.
• Employees: Experienced a corporate restructuring in May 2025, including a 45% reduction in force, which could impact morale and operational stability. Competitive compensation and benefits, including stock options and RSUs, are offered to attract and retain talent.
• Customers/Patients: Potential for new therapeutic options with rinvatercept (DMD, ALS) and elritercept (MDS, myelofibrosis) if clinical trials are successful and products receive regulatory approval. Deprioritization of cibotercept and KER-047 means those potential treatments will not advance.
• Collaborators (Takeda, Hansoh): Takeda is now responsible for further development, manufacturing, and commercialization of elritercept in its territory, while Hansoh continues in its territory. This shifts significant financial and operational burden from Keros.
• Creditors: The company's financial health and ability to raise capital will impact its ability to meet future obligations.

Next Steps

• Commence a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (DMD) in the second quarter of 2026.
• Engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with amyotrophic lateral sclerosis (ALS) in the second half of 2026.
• Continue the Phase 3 RENEW clinical trial for elritercept in lower-risk MDS, with Takeda leading development, manufacturing, and commercialization in the Takeda Territory.
• Hansoh to continue development, manufacture, and commercialization of elritercept in the Hansoh Territory.
• Negotiate in good faith with Hansoh to enter into an agreement for commercial supply of elritercept prior to anticipated commercialization in the Hansoh Territory.
• Distribute 25% of any net cash proceeds received on or before December 31, 2028, from the Takeda Agreement to stockholders.
• Continue to identify and develop product candidates to treat diseases where targeting the TGF-beta signaling pathways has clinical validation or biological rationale, including neuromuscular and neurodegenerative disorders, rare bone and fibrosis diseases, and obesity and frailty indications.

Key Dates

Recommendation

The company's 2025 net income is a positive, but it's largely due to a one-time licensing payment, and the company anticipates future losses. While the Takeda deal and clinical progress for rinvatercept and elritercept are encouraging, the deprioritization of other assets and the significant capital return program (which reduced cash) introduce a degree of uncertainty. The cash runway into H1 2028 is adequate for near-term operations, but substantial additional funding will be required. The stock has seen significant volatility, and while there are promising developments, the inherent risks of clinical-stage biopharmaceutical development and intense competition warrant a 'hold' stance for now, awaiting further clinical data and sustained operational profitability.

Keywords

Keros Therapeutics, KROS, Biopharmaceutical, Clinical-stage, Rinvatercept, KER-065, Duchenne Muscular Dystrophy, DMD, Amyotrophic Lateral Sclerosis, ALS, Elritercept, KER-050, Myelodysplastic Syndromes, MDS, Myelofibrosis, Cytopenias, Anemia, Thrombocytopenia, Takeda Pharmaceuticals, Hansoh Healthtech, SEC Filing, 10-K, Financial Results, Clinical Trials, Drug Development, Intellectual Property, Corporate Governance, Stock Repurchase, Capital Return, TGF-beta signaling, Orphan Drug Designation, Fast Track Designation